Therapy of L3.6pl pancreatic tumors in nude mice with C225 and gemcitabine
| Therapya | Incidence of macroscopic tumorsb | Total pancreas weight mg (range)e | Median tumor volume mm3 (range)f | Median body weight g (range) | ||||
|---|---|---|---|---|---|---|---|---|
| Pancreas tumor | Liver metastasisc | Regional LN metastasisd | ||||||
| Control | 10 /10 | 5 /10 | 10 /10 | 923 (660–1371) | 539 (254–860) | 22 (16–24) | ||
| Gemcitabine | 10 /10 | 3 /10 | 6 /10 | 297 (205–485) | 152 (59–365) | 22 (18–29) | ||
| C225 | 5 /10 | 2 /10 | 8 /10 | 119 (97–157) | 0.3 (0–13) | 25 (21–28) | ||
| C225+ gemcitabine | 0 /9 | 0 /9 | 1 /9 | 130 (93–173) | 0 (0) | 23 (20–27) | ||
a L3.6pl cells (1 × 106) were implanted into the pancreas. Therapy began on day 7, when median tumor size was 18 mm3. C225 (1 mg), Gemcitabine (250 mg/kg), alone or in combination, was injected i.p. biweekly for 4 weeks. Control mice received saline. Tumor weight and metastases were evaluated at necropsy at day 32. One experiment of two is shown.
b Number of tumor-positive mice per number of mice receiving injections.
c Number of mice with visible nodules (>1 mm in diameter) per number of mice receiving injections.
d Number of mice with enlarged regional lymph nodes (LN) per number of mice receiving injections.
e P < 0.0001 (unpaired Student’s t test) control versus all three therapy groups.
f Tumor volume was calculated by the formula: v = ab2/2, where a is the longest diameter and b is the shortest diameter of the tumor. P < 0.0001 control versus all three therapy groups and C225 versus C225 plus gemcitabine therapy group.